Skyrizi

AbbVie Wins FDA Approval to Start Skyrizi at Home: What the Crohn's Decision Means for ABBV Stock

2026-10-24

The FDA approved an at-home way to start one of AbbVie's biggest drugs on October 23, 2026 — and Wall Street barely blinked. AbbVie (NYSE: ABBV) closed Friday at $285.64, up just $0.45, or 0.16%, a...